← boardnext 2027-03
SPTX
Seaport Therapeuticsdistress 1/10 · well-funded / low risk$21.68+2%today-4% from 52w high
Lead: Major Depressive Disorder (MDD) · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$213M
Runway
2.6 yrs
Shares 1y
—
Price & events
+9.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.8%
1D
+11.1%
1W
+14.3%
1M
—
3M
—
6M
—
1Y
—
2Y
—
5Y
+9.3%
All
Overview
- Market Cap
- $1.16B
- Volume
- 3.24K
- 52 Week Range
- $15.25 – $22.52
- Total Shares
- 53.53M
- Float Shares
- 28.29M
- Short %
- 5.46%
- % Held by Insiders
- 35.06%
- % Held by Institutions
- 31.93%
- RVOL
- 0.02x
Pipeline stages · 1 programs
SPT-300
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | SPT-300 | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | — | recruiting |
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 2 | SPT-300 | Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress | — | enrolling by invitation |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $38 (+75% upside) · 5 analysts
- 2026-07-15HC Wainwright & Co.Buy
- 2026-05-26CitigroupBuy
- 2026-05-26Leerink PartnersOutperform
- 2026-05-26JP MorganOverweight
- 2026-05-26StifelBuy
Competitors — Major Depressive Disorder (MDD)
- none identified
Recent news
- 2026-07-22Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
- 2026-07-20Q2 Earnings Forecast for SPTX Issued By HC Wainwright - MarketBeat
- 2026-07-15Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
- 2026-07-05Price to earnings forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
- 2026-06-09Stifel reiterates Buy on Seaport Therapeutics stock, $30 target - Investing.com
- 2026-06-08Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Business Wire
- 2026-06-08Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
- 2026-06-08Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.